Our study demonstrates that Class II and Class III MAP2K1 mutations have the potential to initiate aggressive tumour behaviour without concurrent MAPK mutations, as evidenced by patients who developed widespread distant metastases and subsequently died. This evidence concerns the gene MAP2K1 and neoplasm.